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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline
that is a growing public health crisis with a prevalence projected to more than double in the next
20 years. Sleep is frequently impaired in individuals with AD. Further, recent studies have linked
numerous age-related sleep disturbances such as poor sleep efﬁciency and sleep apnea, to future risk of
cognitive impairment. Aggregation of amyloid-b (Ab) into extracellular plaques in the brain is a key step
in AD pathogenesis and likely begins 20 years before the onset of dementia. Ab concentrations in both
humans and mouse models show Ab concentrations rise during wakefulness and fall during sleep, that is,
an Ab diurnal pattern. There is evidence in animal models that changes in sleep time alter Ab deposition,
suggesting that sleep may play a role in AD pathogenesis. A hypothetical model for the role of sleep and
the Ab diurnal pattern in AD pathogenesis is proposed.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Amyloid-b and Alzheimer’s disease pathogenesis
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive cognitive impairment that is a cur-
rent and growing public health crisis that only has minimally
effective treatments. In 2010, more than 5 million Americans aged
65 years were living with AD, and this number is expected to
increase to 13.5 million in 2050 (Alzheimer’s Association, 2010). A
reliable, even modest reduction in the risk of AD would have a
tremendous public health impact. Age is the greatest risk factor for
AD, but the progression to cognitive impairment likely results
from genetic (e.g., ApoE4) and environmental (e.g., exercise, diet,
and sleep) factors that inﬂuence AD pathology (Mayeux and Stern,
2012). Recent evidence in both humans and animal models sug-
gests a possible mechanism through which sleep, likely interact-
ing with other genetic and environmental risk factors, may play a
role in AD pathogenesis.
Deposition of extracellular amyloid-b (Ab) into insoluble pla-
ques in the brain is a key early step in the pathogenesis of AD that
is associated with the aggregation of tau into intracellularlogy, Washington University
lid Ave, St. Louis, MO 63110,
y).
Y-NC-ND license.neuroﬁbrillary tangles, synaptic dysfunction, neuronal loss, and
cognitive impairment (Hardy and Selkoe, 2002; Jack et al., 2010).
The Ab peptide is predominantly produced in the brain by neurons
when amyloid precursor protein (APP) is cleaved by b- and g-
secretases into multiple isoforms of different amino acid lengths
(Strooper et al., 2010). More speciﬁcally, g-secretase cuts the
C-terminal end of the Ab peptide to generate 3 major isoforms,
that is, Ab38, Ab40, and Ab42. Ab isoforms are then secreted into
the interstitial ﬂuid (ISF) through synaptic vesicle exocytosis,
which is a process inﬂuenced by synaptic activity (Cirrito et al.,
2005). The contribution of Ab isoforms to plaque formation var-
ies. Whereas Ab40 is produced at higher concentrations, Ab42 is
more hydrophobic, neurotoxic, and prone to aggregate (Jarrett
et al., 1993). Further, the aggregation of Ab into extracellular pla-
ques has been found to be concentration dependent. In a mouse
model study, neural cells were transplanted from APP23 trans-
genic mice into wild-type mice and Ab levels were measured both
within the neural graft and the surrounding ISF. Ab concentrations
were the highest within the graft and decreased as a function of
the distance from the graft, and a similar gradient pattern was
observed for amyloid plaques (Meyer-Luehmann et al., 2003).
Since all the Ab deposition did not occur only within the grafts, it
was suggested that Ab diffusion into surrounding neural tissue
played a role in plaque formation.
Neuropathologic changes in AD, that is, extracellular amyloid
plaques and intracellular neuroﬁbrillary tangles of aggregated
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entorhinal cortex, hippocampus, and medial temporal lobe (Braak
and Braak, 1991). Ab deposition is probably insufﬁcient to result
in cognitive decline because pathologic studies show that sig-
niﬁcant neuronal and synaptic loss has already occurred by the
time clinical symptoms manifest. Further, amyloid deposition can
be assessed in vivo in humans by positron emission tomography
(PET) with an amyloid tracer, that is, Pittsburgh Compound B
(PiB) that binds to amyloid, or by decreased cerebrospinal ﬂuid
(CSF) Ab42 concentrations. Approximately 25%e30% of in-
dividuals in their eight decade who were cognitively normal that
were assessed by either of these methods have been found to
have amyloid deposition (Mintun et al., 2006; Morris et al., 2009).
The period of amyloid deposition with normal cognitive func-
tioning has been described as “preclinical Alzheimer’s disease”
(Jack et al., 2010; Sperling et al., 2011). Treatment of AD is hy-
pothesized to be the most successful in this preclinical phase
before Ab deposition into Ab-containing plaques and tau aggre-
gation occurs, which causes signiﬁcant cell loss leading to the
onset of clinically detectable cognitive impairment (Morris,
2005).
Amyloid imaging has also shown that Ab deposition co-localizes
anatomically with other imaging abnormalities associated with AD
in many regions of the brain. Abnormalities that co-localize with
PiB-PET include brain atrophy as shown on brain magnetic reso-
nance imaging, hypometabolism measured by ﬂuorodeoxyglucose-
PET, and dysfunction of the default mode network (DMN) as
measured by functional magnetic resonance imaging (Bero et al.,
2011; Buckner et al., 2005). The DMN is the resting state network
most active in the absence of task performance (Raichle et al., 2000)
and has been reported as the ﬁrst network affected by AD (Greicius
et al., 2004). The DMN is associated with episodic memory
(Buckner, 2004), which is a cognitive domain that is impaired early
in AD. Since the DMN is a resting state network and is therefore
synaptically andmetabolicallymore active than other regions of the
brain, this co-localization with AD pathology may be because of
increased Ab production and secretion into the ISF resulting in a
higher local concentration and greater deposition. Additionally,
decreased energy metabolism and atrophy in the brain have also
been correlated with areas of amyloid deposition (Vlassenko et al.,
2010). Because all these imaging abnormalities overlap, these
ﬁndings suggest that increased synaptic activity leading to Ab ag-
gregation into plaques progresses to decreased neuronal metabolic
function and atrophy presumably through neuronal loss. This hy-
pothesis is supported by ﬁndings in the dominantly inherited AD
population (Bateman et al., 2012).
2. Sleep and AD
Sleep serves a restorative function in the brain and is involved
with memory retention. More speciﬁcally, slow-wave sleep (SWS)
plays a critical role in the consolidation of long-termmemory (Born
and Wilhelm, 2012). Good quality sleep involves following a day
and/or night (i.e., diurnal) pattern of alertness and activity during
the day followed by quiescence at night. Cycling several times
through the different sleep stages during the sleep period is also
essential to restorative sleep. Scoring an individual as awake or in a
speciﬁc sleep stage is primarily determined by changes on an
electroencephalogram (EEG) recorded during polysomnography. In
the awake state, the EEG shows low amplitude, high-frequency
ﬂuctuations because of neurons in the cerebral cortex ﬁring irreg-
ularly. As wakefulness gives way to sleep, the low amplitude, high-
frequency activity attenuates as cortical neurons undergo a slow
oscillation (<1 Hz) in membrane potential between a hyper-
polarized state with no neuronal ﬁring to a depolarized state ofintense ﬁring (Massimini et al., 2004). This slow oscillation is the
fundamental cellular process that organizes waveforms seen on
EEG during sleep, that is, sleep spindles and slow waves.
There are 4 sleep stages. The EEG background in rapid eye
movement sleep is similar to the awake state with low amplitude,
mixed-frequency activity. Non-rapid eye movement (NREM) sleep
is characterized by 3 stages that exhibit progressively increased
slow wave activity (SWA): N1 or drowsiness, N2, and N3 or SWS.
During the deeper stages of NREM sleep (N2 and N3) there aremore
high-amplitude slow waves, which likely accounts for the general
decrease in regional synaptic activity during NREM sleep
(Vyazovskiy et al., 2011). These periods of deeper NREM sleep with
increased SWA are hypothesized to decrease synaptic strength to a
level that is energetically sustainable and promotion of synaptic
plasticity and memory (Tononi and Cirelli, 2006).
Nearly all people older than the age of 60 years have disrupted
sleep architecture and decreased SWS (Redline et al., 2004).
Further, aging has also been associated with regional brain atrophy
involving the midline frontal lobe regions (Sowell et al., 2003) and
cognitive decline (Buckner, 2004). These 3 factors have been
independently associated with aging. However, a recent study
found that age-related medial prefrontal cortex gray-matter atro-
phy was associated with reduced NREM SWA in older adults, the
extent of which statistically accounted for the impairment of
overnight sleep-dependent memory retention (Mander et al.,
2013). These recent ﬁndings suggest an additional potential
mechanism that may be linked to the sleep changes that have been
observed in aging that may be contributing to cognitive decline in
older individuals.
Sleep disturbances in individuals with AD are multifaceted and
include increased or decreased total sleep time, nocturnal arousals,
and reversal of the day and/or night sleep pattern (McCurry et al.,
1999). However, these sleep disturbances have been measured in
individuals already exhibiting cognitive impairment and are likely a
manifestation of dementia. Sleep interventions at this stage of AD
may be difﬁcult to both implement and achieve positive beneﬁts.
For example, the incidence of sleep disorders (e.g., sleep apnea) is
increased in patients with AD and continuous positive airway
pressure (CPAP) therapymay slow or improve cognitive functioning
in patients with AD and sleep disordered breathing (SDB) (Ancoli-
Israel et al., 2008; Cooke et al., 2009). However, both the diag-
nosis and treatment of sleep disorders (e.g., SDB) in patients with
AD is challenging because of the patients’ underlying cognitive
dysfunction impeding both the diagnosis via polysomnography and
treatment with CPAP. Therefore, the efﬁcacy of current therapies
(e.g., CPAP) is difﬁcult to assess in an AD patient population
(Yesavage et al., 2003).
Recent research has focused on the risk of developing cognitive
impairment in cognitively-normal individuals with long-term
sleep disturbances. In multiple cross-sectional studies, changes
in sleep duration have been associated with an increased risk of
cognitive impairment. Tworoger et al. (2006) observed that self-
reported difﬁculty sleeping and sleep duration 5 hours/night in
older women was associated with poorer cognitive performance
for general cognition, verbal memory, category ﬂuency, and
attention. Others have shown conﬂicting results including cogni-
tive impairment associated with longer sleep times >11 hours/
night (Faubel et al., 2009) or 9 hours/night (Loerbroks et al.,
2010), but not short sleep time or both short and long sleep time
(Ferrie et al., 2011; Kronholm et al., 2009; Xu et al., 2011). Addi-
tional markers of poor sleep quality, that is, low sleep efﬁciency,
prolonged sleep latency, increased wake after sleep onset, and
increased napping, have all been associated with impaired
cognitive function (Blackwell et al., 2006, 2011; Keage et al., 2012;
Potvin et al., 2012).
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and calculated using cosinor analysis for mesor, amplitude, and
acrophase of the sleep-wake cycle are associated with the risk of
dementia in older women (Tranah et al., 2011). Speciﬁcally, the
mesor is the midline of the oscillation corresponding to the circa-
dian activity, the amplitude is the distance between the peak and
the mesor, and the acrophase is the time corresponding to the peak
of the curve (Fig. 1). In this study, declining amplitude of the sleep-
wake cycle, which signiﬁes the strength of the rhythm based on the
difference between the peak and nadir in activity and delayed
rhythms as determined by the timing of peak activity during the
day (e.g., acrophase) were associated with increased odds of
developing dementia.
Further evidence that sleep disruption results in cognitive
impairment has come from studies of individuals with sleep
disordered breathing. In a prospective study of 298 womenwithout
dementia who had an overnight polysomnogram, 105 were found
to have sleep disordered breathing as deﬁned by an apnea-
hypopnea index 15 events per hour of sleep and an associated
risk of developing mild cognitive impairment or dementia (Yaffe
et al., 2011). This ﬁnding was associated with oxygen desaturation
and a high percentage of sleep time in sleep disordered breathing,
but not sleep fragmentation or sleep duration. In another study,
sleep fragmentation as measured by actigraphic changes in rest and
activity has been demonstrated to result in poor cognitive function
in the absence of sleep disordered breathing evenwhen controlling
for demographic factors, daily hours of rest, and total daily activity
(Lim et al., 2012).
Recently published work also using actigraphy to monitor the
sleep-wake cycle in cognitively normal individuals aged
45e75 years has shown decreased sleep efﬁciency and increased
nap frequency in individuals with amyloid deposition compared
with those similarly aged without amyloid deposition determined
by CSF Ab42 levels (Ju et al., 2013). These cognitively normal in-
dividuals with amyloid deposition most likely have preclinical AD
and will develop cognitive impairment over time. The importance
of this ﬁnding is that all individuals studied were cognitively
normal but shared a statistically signiﬁcant difference in sleep
parameters when separated by amyloid deposition status, whichFig. 1. Example of cosinor curve and terms used to describe a diurnal rhythm: mesor, midlin
time corresponding to the peak of the curve or zenith.supports the hypothesis that sleep disturbances are associated with
AD pathology and precede the onset of cognitive impairment.
3. Ab diurnal pattern
Because of the hypothesized role of Ab in AD pathogenesis, the
metabolism of Ab in the brain has been investigated. Ab concen-
trations in CSF have been shown to be stable over 10e18 months
intervals in individuals with dementia of the Alzheimer’s type
(Andreasen et al., 1999; Kanai et al., 1998). Since CSF Ab levels could
potentially function as a biomarker to follow the effect of thera-
peutic drug trials in individuals with preclinical AD, a study
measuring CSF Ab levels over shorter time intervals was performed
in 15 cognitively normal participants aged 23e78 years (Bateman
et al., 2007). Serial CSF samples were collected every hour for
36 hours via indwelling lumbar catheter and Ab concentrations
were measured by enzyme-linked immunosorbent assay for Ab40,
Ab42, and total Ab. Signiﬁcant variation in Ab levels of 1.5e4 times
were detected with Ab40 and Ab42 and total Ab levels highly
correlated over time indicating that they are likely regulated by
similar processes.
To address the possible correlation between ﬂuctuating Ab
concentrations and time of day or activity levels, a subsequent
study collected serial CSF samples via lumbar catheter every hour
for 36 hours while simultaneously monitoring sleep with ambula-
tory polysomnography and observing activity levels with video
(Huang et al., 2012). Forty-six participants were enrolled in one of
the following 3 groups: (1) young normal controls aged 18e60
years; (2) older adults age>60 years whowere negative for amyloid
deposition by PiB-PET; and (3) older adults aged >60 years age-
matched to group 2 who were positive for amyloid deposition by
PiB-PET. The hourly CSF concentrations of Ab40 and Ab42 were
analyzed using cosinor analysis (Fig.1). A cosine transformationwas
applied to the time variable using 24 hours as the default circadian
cycle and the mesor, amplitude, and acrophase were calculated for
each participant and averaged within each group. Both soluble
Ab40 and Ab42 isoform concentrations ﬂuctuated by 25% over the
collection period and the ﬂuctuations ﬁt a cosine wave, which is
consistent with a diurnal pattern. No correlation between Abe of the oscillation; amplitude, distance between the peak and mesor; acrophase, and
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ﬂuctuate with the sleep-wake cycle after a 6-hour delay (Huang
et al., 2012). Ab40 and Ab42 levels were higher in the CSF during
wakefulness and lower during sleep. Further, the amplitude of the
cosine wave decreased with age from young normal controls to
individuals >60 years who were PiB-PET negative and the ampli-
tude decreased more in individuals >60 years who were PiB-PET
positive for amyloid deposition.
Studies in individuals with and without autosomal dominant AD
mutations, (e.g., presenilin-1 and presenilin-2) replicate and extend
the ﬁndings described previously regarding the Ab diurnal pattern.
The association between Ab deposition and the decreased ampli-
tude of the Ab diurnal pattern has also been found in human sub-
jects with presenilin mutations that cause familial AD. Individuals
who were either presenilin mutation negative or mutation positive
but negative for amyloid deposition by PiB-PET did not show
attenuation of CSF Ab diurnal rhythms, whereas individuals who
were presenilin positive and positive for amyloid deposition did
show attenuation (Roh et al., 2012). Further, a recent study
modeling Ab42 kinetics in presenilin mutation carriers versus
noncarriers found that the fractional turnover rate of soluble Ab42
relative to Ab40 was faster in mutation carriers and correlated with
amyloid deposition, which is consistent with increased deposition
of Ab42 into plaques leading to reduced recovery of Ab42 in CSF
(Potter et al., 2013). Extrapolating to sporadic AD, this ﬁnding may
account for decreased Ab42 levels in individuals with amyloid
deposition. Ab42 is more prone to aggregation into plaques and the
plaques act as a “sink” sequestering Ab42 once amyloid deposition
has begun, thus preventing a rise in concentration over time.
The diurnal Ab pattern has also been observed in animal
models. APP transgenic mice (Tg2576) that develop amyloid
deposition also show an association between the sleep-wake cycle
and brain ISF Ab concentrations (Kang et al., 2009), and soluble Ab
levels are higher in the ISF of APP transgenic mice during wake-
fulness and lower during sleep. These mice have normal sleepFig. 2. Hypothetical model for the role of sleep in Alzheimer’s disease pathogenesis. Abbrev
ﬂuorodeoxyglucose; fMRI, functional MRI; MRI, magnetic resonance imaging; PET, positron e
sleep; SDB, sleep disordered breathing; WASO, wake after sleep onset.when they are young before amyloid deposition. However, once
Ab plaque formation in APP transgenic mice occurs, there is a loss
of the Ab diurnal pattern and, importantly, a markedly disrupted
sleep-wake cycle with increased wakefulness and decreased sleep
during the light phase when the mice would be expected to sleep
(Roh et al., 2012). These observed changes in sleep in transgenic
mice are completely prevented with active immunization of the
mice with Ab42 indicating that the abnormalities in sleep are
because of Ab aggregation in the brain. Finally, modiﬁcation of
sleep time in APP transgenic mice was investigated by Kang et al.
(2009). Sleep deprivation for 21 days increased ISF Ab concen-
trations and accelerated Ab deposition into plaques, whereas
enhancing sleep with an orexin receptor dual antagonist
decreased Ab aggregation into plaques (Kang et al., 2009).
4. Sleep, Ab, and Alzheimer’s disease pathophysiology: a
proposed model
The diurnal Ab pattern is hypothesized to be related to higher
neuronal activity during wakefulness and decreased neuronal
activity during sleep, such as occurs in SWS (Nir et al., 2011).
Synaptic activity has been shown to increase ISF Ab release from
neurons in both the mouse and in humans (Brody et al., 2008;
Cirrito et al., 2005). Loss of this diurnal pattern is likely because
of sequestration of Ab in extracellular amyloid plaques (e.g.,
altered clearance) or altered neuronal ﬁring (e.g., altered pro-
duction). There is evidence to support Ab42 sequestration in
plaques in older individuals with amyloid deposition that leads to
decreased clearance and lower, less variable CSF Ab42 concen-
trations. Production of soluble Ab may be relatively increased
during the sleep period by loss of SWS in the context of aging
and/or sleep disturbances such as sleep apnea or insomnia. The
net effect of these sleep changes is to increase wake time during
the sleep period. More speciﬁcally, the DMN deactivates during
sleep, particularly SWS (Samann et al., 2011). Therefore,iations: Ab, amyloid-beta; CSF, cerebrospinal ﬂuid; DMN, default mode network; FDG,
mission tomography; PIB, Pittsburgh compound B; SE, sleep efﬁciency; SWS, slow wave
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of deactivation of the DMN, relative increases in synaptic and
metabolic neuronal activity, increased soluble CSF Ab levels
during the sleep period, increased Ab aggregation and seques-
tration into plaques, and attenuation of the Ab diurnal pattern.
Although changes in the sleep-wake cycle have been associated
with markers of AD pathology such as amyloid deposition, the
timing, role, and extent of these changes that are associated with
increasing stages of AD neuropathology and cognitive dysfunction
is unclear. Findings in animal models hint that driving Ab con-
centrations up or down with sleep deprivation or sleep induction,
respectively, may affect amyloid aggregation into plaques. This
ﬁnding has not been replicated in humans, but changes of Ab
production by 25%e40% (Jonsson et al., 2012) can completely
protect or cause AD in humans (Jonghe et al., 1999), which sug-
gests that increasing SWS time may decrease or prevent Ab
accumulation. Notably, a 25% change in Ab concentration has been
found between wakefulness and sleep (Huang et al., 2012). An
alternative explanation of the current data is that sleep changes
are a marker for progression of AD pathology rather than a key
event in AD pathogenesis. Further research is needed to differ-
entiate between these hypotheses.
A model for the role of sleep in AD pathogenesis is proposed to
test future hypothesis-driven research (Fig. 2). As previously dis-
cussed, there are numerous changes that occur during aging
including regional brain atrophy (e.g., medial prefrontal cortex)
and changes in sleep parameters, that is, increased wake after
sleep onset, decreased sleep efﬁciency, decreased SWS, and an
increased incidence of sleep disorders (e.g., SDB). These changes
occur in individuals with genetic and environmental risk factors
that affect overall risk of AD. In individuals prone to AD based on
these risk factors, sleep may play a more or less signiﬁcant role in
the development of AD.
The net effect of disturbed sleep parameters in older adults is a
relative increase in synaptic and metabolic activity in the brain
during the sleep period compared with younger individuals.
Therefore, the concentration of Ab in the CSF does not decrease
during sleep as expected and results in attenuation of the Ab
diurnal pattern. Ab concentrations during the sleep period are
maintained at relatively high levels (25% higher than during sleep),
which promotes amyloid deposition that may further feedback to
disturb sleep and elevate Ab levels during sleep.
The regions of the brain most at risk for amyloid deposition in
this proposed model are those that are metabolically most active,
that is, the DMN. Ab deposition in brain regions is important
because the DMN leads to network dysfunction, synaptic dysfunc-
tion, and impaired cognitive functioning. Impaired cognitive func-
tioning and network dysfunction will manifest as hypometabolism
or vice versa. Impaired cognitive function is associated with sleep
disturbances, feeding back to the sleep changes associated with
aging. The net effect is to increase Ab deposition that is a known
marker for AD risk.
5. Recommendations
The proposed model needs further research before recom-
mendations regarding how to modify or improve sleep will miti-
gate the risk of future AD. However, there are 3 general guidelines
that individuals may follow to promote restorative sleep.
1) Adequate sleep time needs to be allowed. For most individuals,
this time is approximately 7e8 hours.
2) Maintaining a consolidated diurnal sleep pattern, ideally day
and/or night, and avoiding sleep fragmentation will allow for
appropriate cycling through sleep stages.3) Sleep disorders such as sleep apnea should be evaluated and
treated.Disclosure statement
The authors have no conﬂicts of interest to disclose.
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